

![]() |
Clinical utility of FDG-PET in amyotrophic lateral sclerosis and Huntington's disease |
|
Authors | ![]() | |
Published in | European Journal of Nuclear Medicine and Molecular Imaging. 2018, vol. 45, no. 9, p. 1546-1556 | |
Abstract | To evaluate the incremental value of FDG-PET over clinical tests in: (i) diagnosis of amyotrophic lateral sclerosis (ALS); (ii) picking early signs of neurodegeneration in patients with a genetic risk of Huntington's disease (HD); and detecting metabolic changes related to cognitive impairment in (iii) ALS and (iv) HD patients. | |
Keywords | Amyotrophic Lateral Sclerosis/diagnostic imaging — Brain — Fluorodeoxyglucose F18 — Humans — Huntington Disease/diagnostic imaging — Positron-Emission Tomography — Radiopharmaceuticals | |
Identifiers | PMID: 29717332 | |
Full text | ||
Structures | ||
Research group | Troubles de mémoire et maladie d'Alzeimer (935) | |
Citation (ISO format) | AGOSTA, Federica et al. Clinical utility of FDG-PET in amyotrophic lateral sclerosis and Huntington's disease. In: European Journal of Nuclear Medicine and Molecular Imaging, 2018, vol. 45, n° 9, p. 1546-1556. doi: 10.1007/s00259-018-4033-0 https://archive-ouverte.unige.ch/unige:114050 |